Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Parkinson Disease in United States

252 results

Sort By:

Imaging Biomarkers of FOG Response to DBS

Study ID: NCT06951906
Start Date: 2024-11-11
End Date: 2030-01
Study Type

Interventional

Study Phase

Phase4

No. of Participants

54

Intervention / Treatment

fMRI

Sponsor

Medical University of South Carolina

Source: clinicaltrials.gov

Share:
Add to list

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Study ID: NCT04165070
Start Date: 2019-12-19
End Date: 2032-02-13
Study Type

Interventional

Study Phase

Phase2

No. of Participants

450

Intervention / Treatment

Pembrolizumab

Carboplatin

Paclitaxel

Pemetrexed

Vibostolimab

Boserolimab

MK-4830

MK-0482

Ifinatamab Deruxtecan (I-DXd)

HER3-DXd

Sponsor

Merck Sharp & Dohme LLC

Source: clinicaltrials.gov

Share:
Add to list

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

Study ID: NCT06107426
Start Date: 2024-01-24
End Date: 2029-05
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

450

Intervention / Treatment
Sponsor

AbbVie

Source: clinicaltrials.gov

Share:
Add to list

Parkinson Progression Marker Initiative Online (PPMI Online)

Study ID: NCT05065060
Start Date: 2021-07-28
End Date: 2041-12
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

500000

Intervention / Treatment

Observation

Sponsor

Michael J. Fox Foundation for Parkinson's Research

Source: clinicaltrials.gov

Share:
Add to list

Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders

Study ID: NCT04061135
Start Date: 2019-09-01
End Date: 2029-03-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

90

Intervention / Treatment

Response Inhibition and Deep Brain Stimulation in Parkinson's disease

Sponsor

University of Alabama at Birmingham

Source: clinicaltrials.gov

Share:
Add to list

Noise-augmented Automatic Speech Recognition for Speech Treatment in Parkinson's Disease

Study ID: NCT06540989
Start Date: 2024-09-01
End Date: 2027-06-30
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

42

Intervention / Treatment

Immediate treatment

Deferred treatment

Sponsor

Teachers College, Columbia University

Source: clinicaltrials.gov

Share:
Add to list

Deep Brain Stimulation (DBS) Retrospective Outcomes Study

Study ID: NCT03664609
Start Date: 2019-03-12
End Date: 2028-12
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

5000

Intervention / Treatment

Deep Brain Stimulation

Sponsor

Boston Scientific Corporation

Source: clinicaltrials.gov

Share:
Add to list

Endurance Exercise & Virtual Reality for Optimizing Cortical Excitability and Neuroplasticity in PD

Study ID: NCT06133283
Start Date: 2024-02-09
End Date: 2026-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

16

Intervention / Treatment

High intensity endurance exercise

Stretching exercise

Virtual reality (VR)-based gaming

Sponsor

The University of Texas Health Science Center at San Antonio

Source: clinicaltrials.gov

Share:
Add to list

First-in-Human Single and Multiple Dose of HL-400

Study ID: NCT06997484
Start Date: 2025-04-25
End Date: 2026-02-27
Study Type

Interventional

Study Phase

Phase1

No. of Participants

54

Intervention / Treatment

HL-400

Placebo

Sponsor

Highlightll Pharmaceutical (USA) LLC

Source: clinicaltrials.gov

Share:
Add to list

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Study ID: NCT06989112
Start Date: 2025-03-27
End Date: 2031-02-19
Study Type

Interventional

Study Phase

Phase3

No. of Participants

600

Intervention / Treatment

Trastuzumab deruxtecan

Rilvegostomig

Pembrolizumab

Carboplatin

Paclitaxel

Docetaxel

Sponsor

AstraZeneca

Source: clinicaltrials.gov

Share:
Add to list